Toshio Kitamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshio Kitamura has a total of 714 co-authors. Here are the top co-authors by number of shared publications:
- Susumu Goyama
Division of Molecular Oncology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan
33 shared publications Toshihiko Oki
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, 02114, USA
22 shared publications- Yutaka Enomoto
Molecular Pharmacology of Malignant Diseases, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-Ku, Japan
22 shared publications Kumi Izawa
Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
20 shared publications- Shuhei Asada
Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan; The Institute of Laboratory Animals, Tokyo Women's Medical University, Tokyo, Japan
19 shared publications Jiro Kitaura
Division of Cellular Therapy/Division of Stem Cell Signaling, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
17 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The correlation between expression levels of the apoptosis-related genes and the venetoclax sensitivity
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The correlation between expression levels of the apoptosis-related genes and the venetoclax sensitivity
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Establishment and characterization of acquired drug-resistant AML cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Establishment and characterization of acquired drug-resistant AML cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Venetoclax (VEN), a selective BCL-2 inhibitor, effectively induces apoptosis in a wide range of malignancies. VEN-based regimens, which combine VEN with either hypomethylating agents or low-dose cytarabine, have markedly improved treatment outcomes in elderly patients with acute myeloid leukemia (AML). However, approximately one third of patients exhibit intrinsic resistance to these regimens, and the majority of initial responders eventually develop acquired resistance. Therefore, intrinsic and acquired resistance to VEN-based regimens remains a major barrier to achieving durable clinical responses in patients with AML. In this study, we aimed to identify effective treatment strategies to overcome VEN resistance. Among the drugs tested in this study, we found that bortezomib (BTZ), a proteasome inhibitor, showed potent synergy with VEN in inducing apoptosis in a wide range of AML cell lines, irrespective of RAS or TP53 mutation status. Mechanistically, BTZ upregulates proapoptotic proteins such as NOXA, BIM, and PUMA, which neutralize MCL1 and promote apoptosis. Notably, NOXA upregulation plays a critical role in the efficacy of the combination of VEN and BTZ. Moreover, BTZ resensitized AML cell lines with acquired resistance to VEN, further supporting its role in overcoming therapeutic resistance. Importantly, the combination of BTZ and VEN significantly prolongs the survival of mice inoculated with a VEN-resistant AML cell line harboring BAX mutations, which are commonly observed in relapsed AML following VEN-based regimens and confer resistance to VEN by inhibiting the BAX-dependent apoptotic pathway. Collectively, this study provides a rationale for the VEN–BTZ combination as a potential strategy to overcome VEN resistance in certain AML subsets.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Venetoclax (VEN), a selective BCL-2 inhibitor, effectively induces apoptosis in a wide range of malignancies. VEN-based regimens, which combine VEN with either hypomethylating agents or low-dose cytarabine, have markedly improved treatment outcomes in elderly patients with acute myeloid leukemia (AML). However, approximately one third of patients exhibit intrinsic resistance to these regimens, and the majority of initial responders eventually develop acquired resistance. Therefore, intrinsic and acquired resistance to VEN-based regimens remains a major barrier to achieving durable clinical responses in patients with AML. In this study, we aimed to identify effective treatment strategies to overcome VEN resistance. Among the drugs tested in this study, we found that bortezomib (BTZ), a proteasome inhibitor, showed potent synergy with VEN in inducing apoptosis in a wide range of AML cell lines, irrespective of RAS or TP53 mutation status. Mechanistically, BTZ upregulates proapoptotic proteins such as NOXA, BIM, and PUMA, which neutralize MCL1 and promote apoptosis. Notably, NOXA upregulation plays a critical role in the efficacy of the combination of VEN and BTZ. Moreover, BTZ resensitized AML cell lines with acquired resistance to VEN, further supporting its role in overcoming therapeutic resistance. Importantly, the combination of BTZ and VEN significantly prolongs the survival of mice inoculated with a VEN-resistant AML cell line harboring BAX mutations, which are commonly observed in relapsed AML following VEN-based regimens and confer resistance to VEN by inhibiting the BAX-dependent apoptotic pathway. Collectively, this study provides a rationale for the VEN–BTZ combination as a potential strategy to overcome VEN resistance in certain AML subsets.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The combination of venetoclax and bortezomib restores sensitivity of venetoclax in multiple acquired venetoclax resistant AML cells.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The combination of venetoclax and bortezomib restores sensitivity of venetoclax in multiple acquired venetoclax resistant AML cells.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The combination of venetoclax and bortezomib exhibited strong synergistic effects in various AML cell lines.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The combination of venetoclax and bortezomib exhibited strong synergistic effects in various AML cell lines.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Information of compounds used in this paper
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Information of compounds used in this paper
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The synergistic effect of bortezomib and venetoclax is highly dependent on the expression of BAX and BAK proteins.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
The synergistic effect of bortezomib and venetoclax is highly dependent on the expression of BAX and BAK proteins.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Changes in body weight of mice inoculated with MOLM-13 VEN-R cells during the course of drug treatment.
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Changes in body weight of mice inoculated with MOLM-13 VEN-R cells during the course of drug treatment.
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Culture conditions of drug-resistant cell lines
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Culture conditions of drug-resistant cell lines
- Open Access
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Information on the primer used in qPCR
- 2 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance
Information on the primer used in qPCR